Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aditya Patel

Interventional Pain Medicine Hackensack, NJ Medical Doctor

NPI 1134410236 CMS profile 993873

146 N State Rt 17 Ste 2, Rm 205, Hackensack, NJ 07601

Open in the dashboard

General payments

$8,230

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aditya Patel of Hackensack, NJ is reported in the CMS Open Payments database as having received $8,230 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $180 3
2024 General $343 4
2023 General $1,183 16
2022 General $2,469 45
2021 General $2,712 60
2020 General $1,270 24
2019 General $72 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aditya Patel
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Aditya Patel were reported at $180. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Aditya Patel Interventional Pain Medicine median Middle half National median
2019 $72 $684 $216–$2,079 $163
2020 $1,270 $382 $122–$1,109 $114
2021 $2,712 $552 $167–$1,554 $132
2022 $2,469 $605 $187–$1,924 $149
2023 $1,183 $671 $195–$1,915 $160
2024 $343 $684 $206–$1,837 $164
2025 $180 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,992 116 payments
  2. Nevro Corp. $676 7 payments
  3. Boston Scientific Corporation $389 6 payments
  4. NuVasive, Inc. $274 2 payments
  5. Vertos Medical, Inc. $205 3 payments
  6. Foundation Fusion Solutions, LLC $194 2 payments
  7. Stryker Corporation $162 1 payment
  8. Celgene Corporation $55 1 payment
  9. Bioventus LLC $36 1 payment
  10. Janssen Pharmaceuticals, Inc $32 1 payment
  11. Other $215 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,230 154 payments
Products named General payments · program years 2019–2025
  1. Proclaim IPG $2,226 52 payments
  2. PROCLAIM $2,212 37 payments
  3. Neuromodulation Dspsbls and Accs $819 18 payments
  4. Senza $555 6 payments
  5. Proclaim Family of SCS IPGs $344 4 payments
  6. SPECTRA WAVEWRITER $215 2 payments
  7. mild Device Kit $205 3 payments
  8. AttraX $171 1 payment
  9. ETERNA $163 2 payments
  10. OASYS $162 1 payment
  11. Other $909 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

910

Median for Interventional Pain Management: 1,220

Drug cost

$9,899

Median for Interventional Pain Management: $39,344

Branded share of claims

1.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 59 $5,204
Meloxicam Generic 230 $949
Methylprednisolone Generic 127 $936
Tizanidine Hcl Generic 74 $672
Cyclobenzaprine Hcl Generic 216 $552
Ibuprofen Generic 42 $318
Gabapentin Generic 33 $299
Nabumetone Generic 22 $287
Pregabalin Generic 25 $251
Tramadol Hcl Generic 47 $138

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$51,515

Of which drugs: $147

Medicare patients

150

Average age 71

Services billed

766

109 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 39%
Ischemic heart disease 33%
Depression 29%
Osteoporosis 25%
Chronic kidney disease 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 172 $135

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record